CardioRenal Effects of SGLT2 Inhibition in Kidney Transplant Recipients

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 25, 2022

Primary Completion Date

July 31, 2026

Study Completion Date

August 31, 2026

Conditions

Kidney Transplant; ComplicationsDiabetes Mellitus, Type 2

Interventions

DRUG

Empagliflozin10Mg Tab

Empagliflozin10 Mg daily or placebo daily for 18 months

DRUG

Placebo

10Mg Placebo Tab

Trial Locations (1)

RECRUITING

Duke University Medical Center, Durham